KRYS Stock Analysis: Buy, Sell, or Hold?
KRYS - Krystal Biotech, Inc. Common Stock
$260.95
2.04 (0.79%)
▲
5d:
+3.8%
30d:
-1.53%
90d:
+5.84%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
KRYS is down 5.8% this week, but smart money is accumulating calls. Top strike: $260 2026-05-15 with 46 OI. Call ratio: 96% View Scanner →
Strength: 7.5/10
Get Alerted When KRYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KRYS trading at deep discount. Market pricing in -4.3% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: KRYS trading at deep discount. Market pricing in -4.3% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$515.05
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$319.81
18.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KRYS is currently trading at $260.95, which is considered fair relative to its 30-day fair value range of $249.33 to $266.67. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.7) compared to its historical average (28.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.3% over the next few years. This pessimistic expectation contrasts with the company's recent 11.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is approaching resistance at $264.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KRYS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $314.00 (+20.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is approaching resistance at $264.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KRYS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $314.00 (+20.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$249.33 -
$266.67
Company Quality Score
63/100
(BUY)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.3% below Wall St target ($314.00)
Fair Price Analysis
30-Day Fair Range
$249.33 -
$266.67
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$20.04
(7.7%)
Support & Resistance Levels
Support Level
$242.00
Resistance Level
$264.00
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.67
Wall Street Target
$314.00
(+20.3%)
Revenue Growth (YoY)
17.5%
Earnings Growth (YoY)
11.6%
Profit Margin
52.6%
Valuation Discount vs History
-4.3% cheaper
PE vs Historical
24.7 vs 28.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.3%
(market-implied from PE analysis)
1-Year Target
$249.73
(-4%)
2-Year Target
$238.99
(-8%)
3-Year Target
$228.71
(-12%)
3-Yr Target (if PE normalizes)
(PE: 25→28)
$260.56
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.7, Growth: 36.8%)
$668.31
(+156%)
Base:
(SPY PE: 20.6, Growth: 36.8%)
$557.34
(+114%)
Bear:
(PE: 17.5, Growth: 36.8%)
$473.74
(+82%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 36.80 | Current EPS (TTM): $6.84
Bull Case
$439.36
(+76%)
Analyst growth 58.7%, PE expands to 40.5
Base Case
$399.42
(+60%)
Market implied 58.7%, PE stable at 36.8
Bear Case
$171.14
(-32%)
Severe decline -20.0%, PE contracts to 31.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.7 to 28.1
Stabilization Target:
$297.28
(+13.9%)
PE Expansion Potential:
+13.9%
Share & Embed Analysis
Last updated: April 03, 2026 12:39 AM ET
Data refreshes hourly during market hours. Next update: 1:39 AM
Data refreshes hourly during market hours. Next update: 1:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KRYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Suma Krishnan
SELL
25000 shares
2026-03-04
Kathryn Romano
SELL
750 shares
2026-03-02
Daniel Janney
SELL
11803 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
Advanced KRYS Option Strategies
Professional options setups generated by AI based on today's KRYS price and gamma walls.
